Adma Biologics (ADMA) Inventory (2011 - 2025)

Adma Biologics has reported Inventory for 14 years, with the latest figure at $206.5 million in Q4 2025.

• For the quarter ending Q4 2025, Inventory rose 21.28% year-over-year to $206.5 million; the trailing twelve-month figure through Dec 2025 stood at $206.5 million (up 21.28% YoY), and the FY2025 full-year result was $206.5 million, up 21.28% from the prior year.
• Inventory for Q4 2025 stood at $206.5 million, up from $196.7 million in the prior quarter.
• The five-year high for Inventory was $206.5 million in Q4 2025, with the low at $94.1 million in Q1 2021.
• Historically, Inventory has averaged $158.6 million across 5 years, with a median of $163.6 million in 2022.
• Annual changes were most pronounced in 2021 — Inventory soared 80.05% — and 2025, when it dropped 3.12%.
• Adma Biologics' Inventory stood at $124.7 million in 2021, then soared by 30.91% to $163.3 million in 2022, then rose by 5.9% to $172.9 million in 2023, then slipped by 1.54% to $170.2 million in 2024, then rose by 21.28% to $206.5 million in 2025.
• The last three Inventory figures came in at $206.5 million (Q4 2025), $196.7 million (Q3 2025), and $191.5 million (Q2 2025), per Business Quant data.